A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cardiovascular Diseases
- Hypogonadism
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 45 years and 80 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03518034
- Collaborators
- AbbVie; Acerus Pharmaceuticals Corporation/ Aytu Biosciences Inc.; Allergan Sales LLC; Endo Pharmaceuticals; Upsher-Smith Laboratories LLC
- Investigators
- Study Director: ABBVIE INC. AbbVie
Get Well Soon